Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright 24th Annual Global Investment Conference
Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) announced that President and CEO Ted White will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 14, 2022, at 3:30 p.m. ET. The event emphasizes Verrica's focus on dermatology therapeutics, particularly the late-stage product candidate VP-102, which aims to treat molluscum contagiosum and other skin conditions. Additionally, Verrica has secured a worldwide license agreement with Lytix Biopharma AS for LTX-315 targeting dermatologic oncology.
- Presentation at H.C. Wainwright conference may boost investor interest.
- VP-102 is positioned to address significant unmet needs in dermatology.
- None.
WEST CHESTER, Pa., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica President and CEO, will present at the H.C. Wainwright 24th Annual Global Investment Conference on Wednesday, September 14, 2022 at 3:30 p.m. ET.
Participants may access a live webcast of the event through the following link: https://journey.ct.events/view/f4644667-cfc0-4e04-9eea-ad7eb829da8e.
The webcast can also be accessed in the Investors/Presentations & Events section of the Verrica website at www.verrica.com. The webcast replay will be available shortly after conclusion of the event for 30 days.
About Verrica Pharmaceuticals Inc.
Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica’s late-stage product candidate, VP-102, is in development to treat molluscum contagiosum, common warts and external genital warts, three of the largest unmet needs in medical dermatology. The Company has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatologic oncology conditions. For more information, visit www.verrica.com.
FOR MORE INFORMATION, PLEASE CONTACT:
Investors:
Terry Kohler
Chief Financial Officer
484.453.3296
info@verrica.com
William Windham
Solebury Trout
646.378.2946
wwindham@soleburytrout.com
Media:
Zara Lockshin
Solebury Trout
646.378.2960
zlockshin@soleburytrout.com
FAQ
What is the date and time of Ted White's presentation at the H.C. Wainwright conference?
What product is Verrica Pharmaceuticals developing for dermatology?
What license agreement has Verrica Pharmaceuticals entered into?
